Structure Therapeutics (GPCR), which his working on next-gen oral obesity medication, has emerged as the next top M&A target for Big Pharma, Axios’ Katherine Davis reports. The new market for obesity drugs has reshaped dealmaking in biopharma, as big companies look to replace expiring patents and buy into the fast-growing business, the author notes.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.